Cargando…

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV

Vesicular stomatitis virus (VSV) remains an attractive platform for a potential HIV-1 vaccine but hurdles remain, such as selection of a highly immunogenic HIV-1 Envelope (Env) with a maximal surface expression on recombinant rVSV particles. An HIV-1 Env chimera with the transmembrane domain (TM) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azizi, Hiva, Knapp, Jason P., Li, Yue, Berger, Alice, Lafrance, Marc-Alexandre, Pedersen, Jannie, de la Vega, Marc-Antoine, Racine, Trina, Kang, Chil-Yong, Mann, Jamie F. S., Dikeakos, Jimmy D., Kobinger, Gary, Arts, Eric J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223473/ https://www.ncbi.nlm.nih.gov/pubmed/37243081 http://dx.doi.org/10.3390/vaccines11050977

Ejemplares similares

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
por: Jelinski, Joseph, et al.
Publicado: (2023)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
por: Cross, Robert W., et al.
Publicado: (2020)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
por: Legardy-Williams, Jennifer K., et al.
Publicado: (2020)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
por: Kainulainen, Markus H., et al.
Publicado: (2023)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
por: Vianello, Eleonora, et al.
Publicado: (2022)

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas
por: Schwartz, David A.
Publicado: (2020)

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
por: Davis, Chris, et al.
Publicado: (2019)

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
por: Boum, Yap, et al.
Publicado: (2020)

Titration methods for rVSV-based vaccine manufacturing
por: Gélinas, Jean-François, et al.
Publicado: (2020)

Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines
por: Coller, Beth-Ann G., et al.
Publicado: (2022)

28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials
por: Simon, Jakub, et al.
Publicado: (2020)

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
por: Halperin, Scott A, et al.
Publicado: (2019)

Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
por: Wright, KJ, et al.
Publicado: (2012)

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
por: Monath, Thomas P., et al.
Publicado: (2019)

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
por: Henao-Restrepo, Ana Maria, et al.
Publicado: (2017)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
por: Cao, Wenguang, et al.
Publicado: (2023)

Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine
por: Yang, Zeyu, et al.
Publicado: (2023)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
por: Santoro, Francesco, et al.
Publicado: (2021)

Bioreactor production of rVSV‐based vectors in Vero cell suspension cultures
por: Kiesslich, Sascha, et al.
Publicado: (2021)

Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor
por: Ton, Christopher, et al.
Publicado: (2023)

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus
por: Dong, Fangfang, et al.
Publicado: (2019)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
por: Sorvillo, Teresa E., et al.
Publicado: (2021)

Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses
por: Racine, Trina, et al.
Publicado: (2017)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
por: Makovitzki, Arik, et al.
Publicado: (2021)

Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs
por: Madar-Balakirski, Noa, et al.
Publicado: (2022)

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
por: Gillespie, Paul F., et al.
Publicado: (2023)

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
por: Fuchs, JD, et al.
Publicado: (2012)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
por: Nyombayire, Julien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_15i2i9846bggo9bv6ogilhnnf3